Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Kansainvälinen, monikeskus, avoin satunnaistettu faasi III -tutkimus, jolla arvioitiin adjuvantin durvalumabin lisäämisen hyöty neoadjuvanttikemoterapian ja durvalumabin jälkeen potilailla, joilla on vaiheen IIB-IIIB (N2) leikattavissa oleva NSCLC (ADOPT-lung)

tiistai 3. marraskuuta 2026 päivittänyt: ETOP IBCSG Partners Foundation

ADOPT-lung is an international, multicentre, open-label randomised phase III trial. Protocol treatment consists of 3-4 cycles of neoadjuvant durvalumab in combination with platinum-based doublet chemotherapy, followed by surgery. Patients with R0 and R1 only resection will be randomised to receive either adjuvant durvalumab for 12 cycles (experimental arm) or observation (control arm). The primary objective of the study is to determine whether additional adjuvant immunotherapy with durvalumab after neoadjuvant chemo-immunotherapy has an effect on disease-free survival (DFS) in patients who do not achieve complete pathological response (pCR) as per local assessment according to the IASLC recommendations.

Tutkimuksen yleiskatsaus

Tila

Rekrytointi

Ehdot

Interventio / Hoito

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

290

Vaihe

  • Vaihe 3

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Tutki yhteystietojen varmuuskopiointi

Opiskelupaikat

  • Alankomaat
      • Amsterdam, Alankomaat
        • Rekrytointi
        • NKI
        • Ottaa yhteyttä:
      • Utrecht, Alankomaat
  • Australia
    • New South Wales
      • Camperdown, New South Wales, Australia
        • Ei vielä rekrytointia
        • Chris O'Brien Lifehouse
        • Ottaa yhteyttä:
          • Malinda Itchins
      • Penrith, New South Wales, Australia
        • Rekrytointi
        • Nepean Hospital
        • Ottaa yhteyttä:
          • Deme Karikios
      • St Leonards, New South Wales, Australia
        • Rekrytointi
        • Royal North Shore Hospital
        • Ottaa yhteyttä:
          • Malinda Itchins
    • Queensland
      • Woolloongabba, Queensland, Australia
        • Ei vielä rekrytointia
        • Princess Alexandra Hospital
        • Ottaa yhteyttä:
          • Kenneth O'Bryne
    • South Australia
      • Bedford Park, South Australia, Australia
        • Ei vielä rekrytointia
        • Flinders Medical Centre
        • Ottaa yhteyttä:
          • Chris Karapetis
    • Tasmania
      • Hobart, Tasmania, Australia
        • Ei vielä rekrytointia
        • Royal Hobart Hospital
        • Ottaa yhteyttä:
          • Rebecca Tay
    • Victoria
      • Box Hill, Victoria, Australia
        • Rekrytointi
        • Eastern Health
        • Ottaa yhteyttä:
          • Phillip Parente
      • Melbourne, Victoria, Australia
        • Rekrytointi
        • Alfred Hospital
        • Ottaa yhteyttä:
          • Maggie Moore
      • Parkville, Victoria, Australia
        • Rekrytointi
        • Peter MacCallum Cancer Centre
        • Ottaa yhteyttä:
          • Benjamin Solomon
    • Western Australia
      • Nedlands, Western Australia, Australia
        • Ei vielä rekrytointia
        • Sir Charles Gairdner Hospital
        • Ottaa yhteyttä:
          • Samantha Bowyer
  • Belgia
      • Anderlecht, Belgia
      • Antwerp, Belgia
        • Rekrytointi
        • Antwerp University Hospital
        • Ottaa yhteyttä:
          • Reinier Wener
  • Irlanti
      • Dublin, Irlanti
      • Dublin, Irlanti
        • Rekrytointi
        • St James's Hospital
        • Ottaa yhteyttä:
  • Italia
      • Alessandria, Italia
        • Ei vielä rekrytointia
        • SS Antonio e Biagio e Cesare Arrigo Hospital
        • Ottaa yhteyttä:
      • Padova, Italia
      • Perugia, Italia
      • Rome, Italia
        • Rekrytointi
        • Istituto Nazionale Tumori "Regina Elena"
        • Ottaa yhteyttä:
      • Siena, Italia
        • Ei vielä rekrytointia
        • AOUS Policlinico Le Scotte
        • Ottaa yhteyttä:
      • Verona, Italia
        • Rekrytointi
        • Universita di Verona - Department of Medicine
        • Ottaa yhteyttä:
  • Itävalta
  • Ranska
  • Sveitsi
      • Baden, Sveitsi
        • Ei vielä rekrytointia
        • Kantonsspital Baden
        • Ottaa yhteyttä:
      • Basel, Sveitsi
        • Rekrytointi
        • Universitätsspital Basel
        • Ottaa yhteyttä:
      • Bellinzona, Sveitsi
      • Bern, Sveitsi
      • Fribourg, Sveitsi
      • Lausanne, Sveitsi
      • Sankt Gallen, Sveitsi
        • Rekrytointi
        • Kantonsspital St.Gallen
        • Ottaa yhteyttä:
      • Winterthur, Sveitsi
        • Rekrytointi
        • Kantonsspital Winterthur
        • Ottaa yhteyttä:
      • Zurich, Sveitsi
  • Viro
  • Yhdistynyt kuningaskunta
      • Cardiff, Yhdistynyt kuningaskunta
        • Rekrytointi
        • Velindre University NHS Trust
        • Ottaa yhteyttä:
          • Paul Shaw
      • Glasgow, Yhdistynyt kuningaskunta
        • Ei vielä rekrytointia
        • Beatson West of Scotland Cancer Centre NHS Greater Glasgow and Clyde
        • Ottaa yhteyttä:
          • Nicola Steele
      • London, Yhdistynyt kuningaskunta
      • London, Yhdistynyt kuningaskunta
        • Ei vielä rekrytointia
        • Royal Marsden Hospital (Chelsea)
        • Ottaa yhteyttä:
      • London, Yhdistynyt kuningaskunta
        • Ei vielä rekrytointia
        • Royal Marsden Hospital (Sutton)
        • Ottaa yhteyttä:
      • Maidstone, Yhdistynyt kuningaskunta
        • Rekrytointi
        • Maidstone and Tunbridge Wells NHS Trust
        • Ottaa yhteyttä:
      • Manchester, Yhdistynyt kuningaskunta
        • Rekrytointi
        • Wythenshawe Hospital, Manchester University NHS Foundation Trust
        • Ottaa yhteyttä:

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria for enrolment:

  • Histologically confirmed NSCLC.
  • Stage IIB-IIIB (T1-4 N0-2) according to 8th edition of the TNM staging system of lung cancer.

Stage III assessment should include samples of lymph nodes at levels 4, bilaterally, and level 7 to rule out stage IIIB N3 disease.

T4 tumours will only be eligible if they are defined as T4 based only on their size (>7cm); any other reason will be considered ineligible.

  • Known PD-L1 status, as tested locally using a validated assay. To ensure comparability of results, it is strongly encouraged that PD-L1 testing is done with the Ventana PD-L1 (SP263) assay.
  • Absence of EGFR mutation or ALK translocation, as tested locally.
  • Primary tumour resectable and functionally operable as assessed per local multidisciplinary tumour board (cardiac evaluation, pulmonary function and diffusion capacity, comorbidity).
  • Adequate haematological function:

Haemoglobin ≥90 g/L, Absolute neutrophil count (ANC) ≥1.0× 109/L, Platelet count ≥75× 109/L.

- Adequate renal function: Measured creatinine clearance (CL) >40 mL/min or calculated CL >40 mL/min calculated by the Cockcroft-Gault.

- Adequate liver function: ALT and AST ≤2.5× institutional ULN, Total serum bilirubin ≤1.5× institutional ULN (patients with Gilbert's syndrome may be allowed to be enrolled after consultation with the Medical Affairs Team at the ETOP IBCSG Partners Foundation.

  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
  • Age ≥18 at the time of enrolment.
  • Body weight >30 kg.
  • Life expectancy of at least 12 weeks.
  • Women of childbearing potential, including women who had their last menstruation in the last 2 years, must have a negative urinary or serum pregnancy test at screening before enrolment. Pregnancy test must be repeated within 3 days before the first dose of protocol treatment.
  • Written IC for study participation must be signed and dated by the patient and the investigator prior to any study-related intervention.

Eligibility Criteria for randomisation:

  • Surgical resection must have been completed. Note: Participants who have had only had segmentectomy or wedge resections are not eligible for randomisation.
  • Patients must have complete resection: R0 or R1 resection.
  • Patients must be fit to receive adjuvant treatment with durvalumab.
  • Patients must have no evidence of metastatic disease as assessed by CT scan.
  • Documentation of pathological response as per local review must be available.

Exclusion Criteria for enrolment:

  • T4 with invasion of heart, great vessels, carina, trachea, oesophagus, or spine.
  • Any previous or concurrent treatments for NSCLC.
  • Any previous immunotherapy.
  • Major surgical procedure (as per investigators assessment) within 28 days before enrolment.
  • History of allogenic organ transplantation.
  • Active or prior documented autoimmune disease or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.]). The following are exceptions to this criterion:

Patients with vitiligo or alopecia. Patients with type I diabetes. Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement.

Any chronic skin condition that does not require systemic therapy. Patients without active disease in the last 5 years may be included but only after consultation with the Medical Affairs Team at the ETOP IBCSG Partners Foundation.

Patients with celiac disease controlled by diet alone.

  • Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease (ILD), or serious chronic gastrointestinal conditions associated with diarrhoea.
  • Psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.
  • History of another primary malignancy except for:

Malignancy treated with curative-intent and with no known active disease 5 years before the first dose of durvalumab and of low potential risk for recurrence.

Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.

Adequately treated carcinoma in situ without evidence of disease.

  • History of leptomeningeal carcinomatosis.
  • History of active primary immunodeficiency.
  • Active hepatitis infection, positive hepatitis C virus (HCV) antibody, hepatitis B virus (HBV) surface antigen (HbsAg) or HBV core antibody (anti-HBc).

Participants with a past or resolved HBV infection (defined as the presence of anti-HBc and absence of HbsAg) are eligible.

Participants positive for HCV antibody are only eligible if polymerase chain reaction is negative for HCV RNA.

  • Known HIV infection that is not well-controlled. All of the following criteria are required to define an HIV infection that is well controlled: undetectable viral RNA load for 3 months, CD4+ count of 500 cell per mm3, no history of AIDS-defining opportunistic infection within the past 12 months, and stable for at least 3 months on the same anti-HIV medication.
  • Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion:

Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection).

Systemic corticosteroids at physiologic doses not exceeding 10 mg/day of prednisone or its equivalent.

Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).

- Receipt of live attenuated vaccine within 30 days prior to the first dose of durvalumab.

Note: Patients in the ADOPT-lung trial, should not receive live vaccine whilst receiving durvalumab and for up to 30 days after the last dose.

Concurrent enrolment in another interventional clinical trial.

  • Known allergy or suspected hypersensitivity to durvalumab or its excipients.
  • Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.
  • Female patients who are pregnant or in the period of lactation.
  • Female patients of childbearing potential and sexually active men who are not willing to use a highly effective contraceptive method during the trial until at least 90 days after the last dose of protocol treatment.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Durvalumab

Protocol treatment in the adjuvant phase consists of adjuvant durvalumab
Lääke: Adjuvant durvalumab

Durvalumab is given at a fixed dose of 1500 mg i.v. every 4 weeks (±1 week) until relapse or unacceptable toxicity, for a maximum of 12 cycles after surgery.
Ei väliintuloa: Observation

Observation only

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Disease-free survival (DFS)
Aikaikkuna: From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)

Assessed in the adjuvant treatment phase.

DFS is defined as the time from the date of randomisation until disease recurrence (including loco-regional recurrence, a distant (metastatic) recurrence or a second primary) or death from any cause. Censoring (for patients without recurrence/death) will occur at the date of last tumour assessment. Patients without a post-randomisation tumour assessment will be censored at the date of randomisation (plus 1 day). DFS will be assessed in patients without pCR (primary endpoint), as well as in patients with pCR (secondary endpoint) and in patients with/without ctDNA clearance (secondary endpoints).
From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
DFS in patients with pCR
Aikaikkuna: From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)

Assessed in the adjuvant treatment phase (after randomisation).

DFS is defined as the time from the date of randomisation until disease recurrence (including loco-regional recurrence, a distant (metastatic) recurrence or a second primary) or death from any cause. Censoring (for patients without recurrence/death) will occur at the date of last tumour assessment. Patients without a post-randomisation tumour assessment will be censored at the date of randomisation (plus 1 day). DFS will be assessed in patients without pCR (primary endpoint), as well as in patients with pCR (secondary endpoint) and in patients with/without ctDNA clearance (secondary endpoints).
From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
Overall survival (OS) in patients with/without pCR
Aikaikkuna: From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)

Assessed in the adjuvant treatment phase (after randomisation).

OS is defined as the time from the date of randomisation until death from any cause. Censoring (for patients who are not reported as having died) will occur at the date when they were last known to be alive. Patients without post-randomisation information will be censored at the date of randomisation (plus 1 day). OS will be assessed in patients with/without pCR.
From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
DFS in patients with/without ctDNA clearance
Aikaikkuna: From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)

Assessed in the adjuvant treatment phase (after randomisation).
From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
Time to recurrence (TTR) in patients with/without pCR
Aikaikkuna: From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)

Assessed in the adjuvant treatment phase (after randomisation).

TTR is defined as the time from the date of randomisation until disease recurrence. Censoring (for patients without recurrence) will occur at the date of the last tumour assessment. Patients without a post-randomisation tumour assessment will be censored at the date of randomisation (plus 1 day). TTR will be assessed in patients with/without pCR.
From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
Time to treatment discontinuation (TTD) in patients with/without pCR
Aikaikkuna: From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)

Assessed in the adjuvant treatment phase (after randomisation).
From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
Toxicity according to CTCAE v5.0
Aikaikkuna: From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)

Assessed in the adjuvant treatment phase (after randomisation).

All safety parameters will be summarised in tables to evaluate the toxicity/safety profile of the protocol treatment based on:

  • Adverse events according to CTCAE v5.0 (any-cause as well as treatment-related) including adverse events leading to dose interruptions, withdrawal of protocol treatment, and death.
  • Severe, serious, and selected adverse events.
  • Deaths.
  • Laboratory parameters and abnormalities, and vital signs.
From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)

Muut tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Correlation between ctDNA clearance and DFS
Aikaikkuna: From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)

Exploratory endpoint
From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
Correlation between ctDNA clearance and OS
Aikaikkuna: From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)

Exploratory endpoint
From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
Correlation between ctDNA clearance and initial PD-L1 assessment
Aikaikkuna: From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)

Exploratory endpoint
From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
Outcome (event-free survival)
Aikaikkuna: From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)

Outcome (EFS) in patients with patients with either

  • ctDNA clearance after neoadjuvant treatment but not achieving pCR
  • no ctDNA clearance after neoadjuvant treatment but achieving pCR
From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
Correlation of Outcome Disease-free survival (DFS)
Aikaikkuna: From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)

Correlation of Outcome (DFS) in patients with longitudinal ctDNA assessment
From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
Correlation of Outcome Overall survival (OS)
Aikaikkuna: From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)

Correlation of Outcome (OS) in patients with longitudinal ctDNA assessment
From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
pCRDescription of patients entering each phase (e.g., % surgery, % randomised)
Aikaikkuna: From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)

pCRDescription of patients entering each phase (e.g., % surgery, % randomised)
From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

ETOP IBCSG Partners Foundation

Yhteistyökumppanit

AstraZeneca

Tutkijat

  • Opintojen puheenjohtaja: Solange Peters, MD-PhD, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland
  • Opintojen puheenjohtaja: Sabine Schmid, MD, Inselspital, Universitätsspital Bern, 3010 Bern, Switzerland
  • Opintojen puheenjohtaja: Paul Van Schil, MD-PhD, Antwerp University Hospital, Antwerp, Belgium,
  • Opintojen puheenjohtaja: Stephen Finn, MD-PhD, St. James's Hospital, Dublin 8, Ireland

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Keskiviikko 15. tammikuuta 2025

Ensisijainen valmistuminen (Arvioitu)

Maanantai 1. lokakuuta 2029

Opintojen valmistuminen (Arvioitu)

Perjantai 1. maaliskuuta 2030

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Keskiviikko 21. helmikuuta 2024

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Keskiviikko 21. helmikuuta 2024

Ensimmäinen Lähetetty (Todellinen)

Keskiviikko 28. helmikuuta 2024

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Perjantai 6. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Tiistai 3. marraskuuta 2026

Viimeksi vahvistettu

Sunnuntai 1. marraskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Avainsanat

Muita asiaankuuluvia MeSH-ehtoja

Muut tutkimustunnusnumerot

  • ETOP 25-23

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa